丙-2-烯基吡嗪-2-羧酸酯 | 132172-97-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 丙-2-烯基吡嗪-2-羧酸酯
• 英文名称: allyl pyrazinoate
• 英文别名: prop-2-enyl pyrazine-2-carboxylate
• CAS: 132172-97-5
• 化学式: C₈H₈N₂O₂
• mdl: MFCD00900201
• 分子量: 164.164
• InChiKey: PMUVYSFTPNYAAQ-UHFFFAOYSA-N

物化性质

• 沸点：
  275.6±25.0 °C(Predicted)
• 密度：
  1.157±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-氯吡嗪 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 丙-2-烯基吡嗪-2-羧酸酯
  参考文献：
  名称：

  Pyrazinoic acid esters as antituberculosis agents

  摘要：

  已制备吡嗪酸酯。该类化合物对包括结核分枝杆菌、对吡嗪酰胺耐药的结核分枝杆菌、波氏分枝杆菌和堪萨斯分枝杆菌在内的分枝杆菌具有有效作用。

  公开号：

  US04962111A1

文献信息

• Heterobicyclic pyrazole compounds and methods of use
  申请人：Blake F. James

  公开号：US20070238726A1

  公开（公告）日：2007-10-11

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。公开了使用化合物Ia和Ib的结构，以及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐的方法，用于体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理条件。
• Antimycobacterial activity of a series of pyrazinoic acid esters
  作者：Michael H. Cynamon、Sally P. Klemens、Tso Sheng Chou、Rayomand H. Gimi、John T. Welch

  DOI：10.1021/jm00085a007

  日期：1992.4

  A series of pyrazinoic acid esters has been prepared and evaluated for in vitro antimycobacterial activity. Several of the pyrazinoate esters have substantially better activity than the first-line antituberculous agent pyrazinamide against susceptible isolates of Mycobacterium turberculosis as well as activity against pyrazinamide-resistant isolates. The minimal inhibitory concentrations (MICs) were

  已经制备了一系列吡嗪酸酯，并评估了其体外抗分枝杆菌活性。几种吡嗪酸酯具有比一线抗结核剂吡嗪酰胺对结核分枝杆菌易感分离株更好的活性以及对耐吡嗪酰胺分离株的活性。与吡嗪酰胺相比，每种生物在每种pH下的最低抑菌浓度（MIC）均低。该酯具有抗牛津分枝杆菌和堪萨斯分枝杆菌（对吡嗪酰胺有抗性的两种）的活性，但对鸟分枝杆菌复合物没有活性。
• [EN] PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS<br/>[FR] PYRAZOLO-PYRIDINES EN TANT QU'INHIBITEURS DE TYROSINE KINASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2009033084A1

  公开（公告）日：2009-03-12

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  式Ia和Ib化合物的复合物及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。本发明公开了使用式Ia和Ib化合物的复合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐，用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的此类疾病或相关的病理状况的方法。
• HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE
  申请人：Blake James F.

  公开号：US20100256356A1

  公开（公告）日：2010-10-07

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  公式Ia和Ib的化合物及其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。本文揭示了使用公式Ia和Ib的化合物及其立体异构体、几何异构体、互变异构体、溶剂合物和药学上可接受的盐的方法，用于哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件。
• PYRAZOLO-PYRIDINES AS TYROSINE KINASE INHIBITORS
  申请人：DeMeese Jason

  公开号：US20110130406A1

  公开（公告）日：2011-06-02

  Compounds of Formulas Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting receptor tyrosine kinases and for treating disorders mediated thereby. Methods of using compounds of Formula Ia and Ib, and stereoisomers, geometric isomers, tautomers, solvates and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

  化学式Ia和Ib的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物、代谢产物和药学上可接受的盐，可用于抑制受体酪氨酸激酶并治疗由此介导的疾病。本文揭示了使用化学式Ia和Ib的化合物及其立体异构体、几何异构体、互变异构体、溶剂化物和药学上可接受的盐的方法，用于哺乳动物细胞中的体外、体内诊断、预防或治疗这种疾病或相关病理条件。